News

In the light of these results, Ipsen announces its intention to file the first ready-to-use liquid toxin A in Europe and in the Rest of the World (ROW).

A Phase I/II clinical trial will be carried out by Pfizer and Merck that will assess the safety and anti-cancer efficacy of MK-3475 combined with Pfizer’s small molecule

The company previously had exclusive global distribution rights and served as the distributor for DUROLANE in Europe, Canada and Australia. Under the new deal, Galderma will continue to

In May 2011, BioAlliance signed a licensing deal with Sosei to carry out bridging development program and commercialization rights in Japan for Loramyc in the treatment of oropharyngeal

The trial is designed to assess Oxycodone DETERx versus placebo in opioid-experienced and opioid-naïve subjects with moderate-to-severe chronic low back pain. According to company, patients who achieve a

The spray is used to provide 24 hour relief of the full range of seasonal and year-round nasal allergy symptoms, including nasal congestion, in adults and children two

The application covers a system and method of controlling Parkinson’s therapy in response to motor symptoms. The allowed claims include a portable system for measuring, quantifying, and treating

The small molecule inhibitors under development block anthrax lethal toxin. The award has a first-year period of performance, through the first quarter of 2014, valued at $1.1m. The

Averica will provide services to IRIX on a preferred provider basis. Averica Discovery Services supplies a wide variety of chromatography and analytical services to pharmaceutical, biotechnology and other